NASDAQ · CLRB
Cellectar Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CLRB: Nov 12, 2026
Cellectar Biosciences, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.46. The reported EPS for the same quarter last year was $-1.41.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.46 | $-0.42 | $-0.50 | 2 |
| Dec 2026 | $-0.51 | $-0.43 | $-0.59 | 2 |
| Mar 2027 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Jun 2027 | $-0.68 | $-0.68 | $-0.68 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks · Fintel- RTTNews · Oct 27, 8:06 AM EDTCellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up(RTTNews) – Cellectar Biosciences, Inc. (CLRB) reported a case study in which a single administration of its cancer treatment, Iopofosine I 131, resulted in a complete response lasting more than eight years in a patient with aggressive diffuse large B-cell lymphoma (DLBCL).
- RTTNews · Oct 15, 8:31 AM EDTCellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström Patients(RTTNews) – Cellectar Biosciences, Inc. (CLRB) announced positive efficacy findings from a subgroup analysis of its Phase 2b CLOVER WaM trial evaluating iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia (WM) following Bruton tyrosine kinase in
- RTTNews · Sep 29, 7:53 AM EDTCellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia(RTTNews) – Tuesday, Cellectar Biosciences (CLRB) said a Phase 2 CLOVER WaM subset analysis showed encouraging efficacy for iopofosine I 131 in patients with Waldenström macroglobulinemia who were refractory or resistant to BTK inhibitor therapy.
- The Motley Fool · Aug 20, 10:13 AM EDTCellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 13, 7:57 AM EDTCellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline(RTTNews) – Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year.
- RTTNews · Jun 2, 9:43 AM EDTCellectra Reports Positive Phase 2 CLOVER Data For Iopofosine I 131 In Waldenstrom Macroglobulinemia(RTTNews) – Cellectar Biosciences Inc. (CLRB), a late-stage clinical biopharmaceutical company, on Monday released positive results from the Phase 2b CLOVER WaM trial for Iopofosine I 131 in treating patients with relapsed/refractory Waldenstrom macroglobulinemia, including those
- The Motley Fool · May 14, 2:49 PM EDTCellectar (CLRB) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · May 8, 8:17 AM EDTWeekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI(RTTNews) – This week's biotech roundup features the FDA's path forward for Atara's tab-cel, Arvinas' first-in-class PROTAC approval, and Incyte's Jakafi XR securing a regulatory nod. The week also saw Novartis announcing a site closure, Roche striking a $750 million PathAI deal,
- Zacks · May 7, 12:00 PM EDTCellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should KnowCellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · May 7, 9:40 AM EDTHas Centene (CNC) Outpaced Other Medical Stocks This Year?Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
- RTTNews · May 5, 10:17 AM EDTCellectar Share Surge On $140M Financing And Strong 12-Month CLOVER-WaM Phase 2b Data(RTTNews) – Shares of Cellectar Biosciences, Inc. (CLRB) jumped in pre-market trading after the company announced an oversubscribed financing of up to $140 million alongside positive 12-month follow-up results from its Phase 2b CLOVER-WaM study evaluating Iopofosine I 131 in rela
- Fintel · Mar 10, 8:03 PM EDTMaxim Group Upgrades Cellectar Biosciences (CLRB)Fintel reports that on March 10, 2026, Maxim Group upgraded their outlook for Cellectar Biosciences (NasdaqCM:CLRB) from Hold to Buy. Analyst Price Forecast Suggests 1,456.49% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cellectar Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.